Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...

Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...

We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...

Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing ...

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...

SEATTLE, Wash. & VENLO, the Netherlands, February 19, 2026--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and ...

Caris Life Sciences ®  (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.

The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted by A*STAR, and the National Cancer Centre Singapore have launched UNITED 2.0 ...

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the ...